Dienstag, J L <br/><br/>
Lamivudine as initial treatment for chronic hepatitis B in the United States.  [electronic resource] 

 -  The New England journal of medicine  Oct 1999 
 - 1256-63 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0028-4793 
<br/><br/><label>Standard No.: </label>10.1056/NEJM199910213411702  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Alanine Transaminase--blood<br/>DNA, Viral--blood<br/>Double-Blind Method<br/>Female<br/>Hepatitis B e Antigens--blood<br/>Hepatitis B virus--genetics<br/>Hepatitis B, Chronic--blood<br/>Humans<br/>Lamivudine--adverse effects<br/>Liver--pathology<br/>Male<br/>Middle Aged<br/>Mutation<br/>Prospective Studies<br/>Reverse Transcriptase Inhibitors--adverse effects<br/>United States